<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896128</url>
  </required_header>
  <id_info>
    <org_study_id>BRC-394</org_study_id>
    <nct_id>NCT01896128</nct_id>
  </id_info>
  <brief_title>Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke</brief_title>
  <official_title>Use of a Wakefulness-Promoting Agent (Armodafinil) Combined With Neuro-rehabilitation to Improve Neurological Recovery and to Reduce the Incidence of Disability in Patients Who Suffered a Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Burke Rehabilitation Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Burke Rehabilitation Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Armodafinil is an FDA approved medication with wakefulness-promoting properties. It is a
      relatively safe agent with interesting neurochemical effects on the catecholamine system,
      producing an improvement in cognitive function, particularly working memory in humans. When
      combined with intensive task-related training, armodafinil may accelerate motor recovery in
      chronic stroke patients.

      The primary aim of this study is to determine whether administration of armodafinil during
      subacute post-stroke rehabilitation will augment cortical plasticity and enhance motor
      recovery. The primary hypothesis suggests that cortical plasticity will be enhanced by
      armodafinil and, therefore, will induce an improvement in motor function and better
      performances on measures of motor control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fugl-Meyer Assessment of Sensorimotor Function from Baseline to Discharge</measure>
    <time_frame>Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Functional Independence Measure (FIM) from Baseline to Discharge</measure>
    <time_frame>Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fugl-Meyer Assessment of Sensorimotor Function from Baseline to Day 100</measure>
    <time_frame>Day 100</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Functional Independence Measure (FIM) from Baseline to Day 100</measure>
    <time_frame>Day 100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timed 3-Minute Walk Test</measure>
    <time_frame>Day 1, Day 12, Day 50, Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Stroke Scale (NIHSS)</measure>
    <time_frame>Day 1, Day 12, Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-Hole Peg Test</measure>
    <time_frame>Day 1, Day 12, Day 50, Day 100</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Stroke</condition>
  <condition>Cerebrovascular Accident</condition>
  <condition>Hemiparesis</condition>
  <arm_group>
    <arm_group_label>Armodafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg armodafinil administered 2 hours prior to start of therapeutic regimen for 10 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>inactive agent administered 2 hours prior to start of therapeutic regimen for 10 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <arm_group_label>Armodafinil</arm_group_label>
    <other_name>Nuvigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>inactive pill manufactured to mimic Armodafinil 150 mg tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First clinical stroke, either cerebral infarction or intracerebral hemorrhage

          -  Severe hemiparesis as measured by a Fugl-Meyer motor scale score of 0-25

          -  Screening Motricity Index score of 0-83

          -  Date of stroke onset between 7 to 21 days prior to study inclusion

        Exclusion Criteria:

          -  Age less than 18

          -  Previous clinical stroke

          -  Pregnant and/or nursing patients

          -  Major psychiatric history, including psychosis and history of substance abuse

          -  Dementia

          -  Known CNS pathology such as brain tumor

          -  Significant language dysfunction or severe neglect that hinders comprehension,
             participation, and barrier to testing

          -  Seizures

          -  Left ventricular hypertrophy (LVH)

          -  Mitral valve prolapse (MVP)

          -  Severe chronic renal failure or severe hepatic failure

          -  History or current use of anti-epileptic medications, psychostimulants, or
             neuroleptics

          -  Current use of diazepam, phenytoin, propranolol, tricyclic antidepressants, steroidal
             contraceptives, cyclosporine, or theophylline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasquale Fonzetti, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Burke Rehabilitation Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Burke Rehabilitation Hospital</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>July 25, 2015</last_update_submitted>
  <last_update_submitted_qc>July 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Burke Rehabilitation Hospital</investigator_affiliation>
    <investigator_full_name>Pasquale Fonzetti, MD, PhD</investigator_full_name>
    <investigator_title>Associate Director, Memory Evaluation and Treatment Service</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>CVA</keyword>
  <keyword>cerebrovascular accident</keyword>
  <keyword>hemiparesis</keyword>
  <keyword>impairment</keyword>
  <keyword>motor recovery</keyword>
  <keyword>neuroplasticity</keyword>
  <keyword>nuvigil</keyword>
  <keyword>armodafinil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Wakefulness-Promoting Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

